Fig. 6.

Clinical response rates among patients with jPsA (GO-VIVA) and adults with PsA (GO-VIBRANT) through week 52 a JIA ACR30 versus ACR20, b JIA ACR50 versus ACR50, c JIA ACR70 versus ACR70, and d JIA ACR90 versus ACR90. Adult PsA population included only adults with baseline methotrexate use. Proportions of JIA ACR and ACR responders are based on imputed data using last observation carried forward and nonresponder imputation. ACR20/50/70/90 = ≥ 20%/50%/70%/90% improvement from baseline in ACR criteria. JIA ACR30/50/70/90 = ≥ 30%/50%/70%/90% improvement from baseline in three components, without worsening of ≥ 30%/50%/70%/90% in > one of the remaining JIA core measures. ACR American College of Rheumatology, JIA juvenile idiopathic arthritis, jPsA juvenile psoriatic arthritis, PsA psoriatic arthritis